Dronabinol, also known as Marinol.



 A specific form of tetrahydrocannabinol, sold as an appetite stimulant, antiemetic, and sleep apnea reliever.



It is approved by the FDA as safe and effective for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting only.



It is the principal psychoactive constituent enantiomer form trans-Δ⁹-tetrahydrocannabinol, found in cannabis.



It does not include any other tetrahydrocannabinol (THC) isomers or any cannabidiol.



Used  to stimulate appetite and therefore weight gain in patients with HIV/AIDS and cancer, and to treat chemotherapy-induced nausea and vomiting.



It can significant improvement in sleep apnea scores.



Has demonstrated analgesic efficacy in a majority of studies in chronic pain, but for acute pain ii is less conclusive.



It may be efficacious in treating cannabis addiction as it reduces cannabis withdrawal symptoms and the subjective effects of marijuana.



Overdose presentation:  drowsiness, cotton-mouth, euphoria, and tachycardia.



A severe overdose associated with lethargy, slurred speech, decreased motor coordination, and postural hypotension.



It has a low potential for abuse: with 


potential for abuse less than that of cocaine and heroin. 



In the United States, Marinol is a Schedule III drug.



It takes over one hour for Marinol to reach full systemic effect, compared to seconds or minutes for smoked or vaporized cannabis.



Comparisons in the use of cannabis extracts with Marinol in the treatment of cancer cachexia have demonstrated equal efficacy and well-being.



Is a Schedule III controlled substance, while but all other cannabinoids remain Schedule I, except synthetics like nabilone.



Leave a Reply

Your email address will not be published. Required fields are marked *